Bioreperia AB

We are a contract research organization (CRO) that increases the speed of your pre-clinical drug development.
BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) technology platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.
Our goal is to increase the speed and accuracy of pre-clinical drug development for cancer treatment, enabling you to select the lead candidates with the highest potential to succeed in less time.